Navigation Links
AnaptysBio Expands Immunotherapy Portfolio With Anti-PD-1 Antibody Combinations
Date:8/29/2013

SAN DIEGO, Aug. 29, 2013 /PRNewswire/ -- AnaptysBio, Inc., a leader in the discovery and development of therapeutic antibodies, today announced the expansion of its proprietary immunotherapy antibody portfolio to include multiple new combination therapies.  Using its SHM-XEL platform, the Company has recently developed a proprietary anti-PD-1 antibody, known as ANB011, with key differentiating advantages over competitors.  AnaptysBio is concurrently developing novel antibodies against other immune checkpoint receptors, including TIM-3 and LAG-3, which may be applied in combination with ANB011. 

(Logo: http://photos.prnewswire.com/prnh/20111205/SF16052LOGO)

Antibodies to immune checkpoint receptors have recently demonstrated promise in the treatment of various solid tumors, including metastatic melanoma, renal cell carcinoma and non-small cell lung cancer.  Although the normal function of immune checkpoint receptors is to maintain immune homeostasis, they are co-opted by certain tumors to evade immune surveillance.  By blocking the interaction of PD-1, TIM-3 and LAG-3 with their respective ligands, AnaptysBio's immunotherapy portfolio aims to restore immune function in cancer patients across a variety of tumor types.   These antibodies may also be combined with small molecule kinase inhibitors for additional anti-tumor activity.    

In addition to the immunotherapy portfolio described above, AnaptysBio has utilized its SHM-XEL platform to develop a novel antibody pipeline, including programs for pustular psoriasis, atopic dermatitis, muscle wasting disorders, fibrosis and antibody drug conjugate applications.

"We believe combination immunotherapy is an exciting paradigm in oncology and has the potential to provide durable anti-tumor effects for a broad range of patients," said Hamza Suria, president & chief executive officer of AnaptysBio. "Our SHM-XEL platform has permitted us to rapidly generate high potency antibodies against multiple immune checkpoint receptors." 

About AnaptysBio

AnaptysBio is a privately-held company focused on the generation of antibody therapeutics and is the leader in the use of somatic hypermutation (SHM) for antibody discovery and optimization. We are developing a pipeline of novel therapeutic antibody candidates, including differentiated programs in cancer immunotherapy, inflammation, fibrosis, muscle wasting disorders and antibody-drug conjugate applications.  AnaptysBio's proprietary SHM-XEL™ platform, which couples fully human antibody libraries with in vitro somatic hypermutation in mammalian cells to generate high affinity antibodies, replicates key features of the human immune system and overcomes limitations of prior antibody technologies.  By harnessing the natural mechanism of antibody maturation under controlled conditions, SHM-XEL allows for the selection of optimal antibody properties such as high affinity, stability, function, cross-reactivity, epitope diversity and manufacturability. The Company has previously announced partnerships with Merck, Roche, Novartis, Celgene, Gilead, DARPA and DTRA.  Major investors in AnaptysBio include Alloy Ventures, Avalon Ventures, Frazier Healthcare Ventures and Novo A/S.  For more information, visit www.anaptysbio.com.

Contacts:
Julie Rathbun
julie@rathbuncomm.com
206-769-9219


'/>"/>
SOURCE AnaptysBio, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Anaptysbio Expands Leadership Team With Addition Of Dr. Andrew J. Mcknight
2. AnaptysBio Develops Novel Antibody Scaffold With Extreme Thermostability
3. AnaptysBio Awarded U.S. Government Contract To Develop Anti-Ricin Antibodies
4. As Smartphone Usage Expands, Survey Says Nurses and Nursing Students Want Mobile Access to Credible Drug Data
5. BioSurplus Expands, Debuts New 8000 Square Foot Warehouse and Service Facility
6. RxAlly Expands National Network With Addition Of Nineteen Community Pharmacy Organizations Representing Over 2,000 Pharmacies
7. Clinical Interest in BioElectronics Products Expands to the Wound Care Market
8. S1 Biopharma Expands Focus to Include Male Sexual Health
9. PRA Expands Operations in Europe
10. USANA Health Sciences Expands Award-Winning Research and Development Team
11. Particle Sciences Expands its cGMP Capabilities with the Addition of Thin Films
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/8/2017)... , May 8, 2017 MACRA ... transition from fee for service reimbursement. Black Book Research ... 1.       The Market for MIPS Compliance ... 77% of physician practices with 3 or more clinicians ... Solutions by Q4. "Given the magnitude of the changes, ...
(Date:5/6/2017)... , May 5, 2017   Provista , a proven ... than 200,000 customers, today announced Jim Cunniff as ... of executive and business experience to Provista, including most recently ... in California . He assumed his new ... is a great fit for Provista," says Jody Hatcher ...
(Date:5/6/2017)... FALLS, N.Y. , May 5, 2017  Hill-Rom ... that will add approximately 100,000 square feet to its ... in September 2016 its commitment to bring more than ... , where Welch Allyn has maintained a significant ... will help accommodate these new positions, a large portion ...
Breaking Medicine Technology:
(Date:5/22/2017)... ... May 22, 2017 , ... An inventor from Columbia, ... a pen. "My wife’s hand was damaged in a firework accident, so she couldn’t ... people with manual problems." , He then designed and created a prototype for the ...
(Date:5/22/2017)... ... May 22, 2017 , ... Faithfully following pop culture, ... squatted, stretched, jumped, toned and shaped through fitness programs. It carries on to skin ... finished off with an irresistible, radiant smile. CDA has found that just ...
(Date:5/21/2017)... ... May 19, 2017 , ... Chris Cornell, 52, was found dead on the night of ... the most respected lead singers in the rock industry would take his own life, but ... FindaTopDoc investigates how mental illness played a role in the death of Chris Cornell ...
(Date:5/21/2017)... CA (PRWEB) , ... May 20, 2017 , ... ... paragraph styled corporate text designs created specifically for use in Final Cut Pro ... process for all media productions. Pixel Film Studios’ ProParagraph Corporate will deliver a ...
(Date:5/21/2017)... ... 2017 , ... Florida Pain Relief Group, a division of Physician Partners of ... Silver Palm Ave., Melbourne, on Monday, May 22. Initially the clinic will be supervised ... practice, PPOA operates 23 pain management clinics in Florida and the Dallas-Fort Worth, Texas ...
Breaking Medicine News(10 mins):